Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,179,463 papers from all fields of science
Search
Sign In
Create Free Account
Liter Per Hour Per Square Meter
Known as:
(l/h)/m2
, L/h/m2
, Liters per Hour per Square Meter
A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Clinical Data Interchange Standards Consortium Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys
D. Jung
,
Lin Lin
,
H. Jiao
,
Xiaohong Cai
,
Jianxin Duan
,
M. Matteucci
Cancer Chemotherapy and Pharmacology
2011
Corpus ID: 22506044
PurposeTo characterize the pharmacokinetics of the prodrug, TH-302, and its active metabolite, bromo-IPM (Br-IPM), in nonclinical…
Expand
Highly Cited
2007
Highly Cited
2007
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic…
E. Heath
,
K. Bible
,
R. Martell
,
D. Adelman
,
P. LoRusso
Investigational New Drugs
2007
Corpus ID: 7192869
SummaryPurpose: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9…
Expand
2007
2007
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan
M. Bonin
,
S. Pursche
,
+5 authors
M. Bornhauser
Bone Marrow Transplantation
2007
Corpus ID: 10389881
Fludarabine is commonly used in combination with busulfan as part of conditioning regimens before allogeneic stem cell…
Expand
Highly Cited
2004
Highly Cited
2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
K. Mross
,
B. Niemann
,
+4 authors
C. Swenson
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 24630910
PurposeLiposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and…
Expand
Highly Cited
2004
Highly Cited
2004
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
P. Nygren
,
K. Hande
,
+10 authors
S. Belle
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 29709720
BackgroundAprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting…
Expand
Highly Cited
2001
Highly Cited
2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
A. Di Paolo
,
R. Danesi
,
+8 authors
M. del Tacca
Annals of oncology : official journal of the…
2001
Corpus ID: 34297481
BACKGROUND Previous work demonstrated that 5-fluorouracil (5-FU) metabolism is a critical factor for treatment tolerability. In…
Expand
2001
2001
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
M. Rothenberg
,
J. Kuhn
,
+12 authors
D. V. Von Hoff
Annals of oncology : official journal of the…
2001
Corpus ID: 42510728
OBJECTIVES This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and…
Expand
Highly Cited
2000
Highly Cited
2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
G. Bocci
,
R. Danesi
,
+8 authors
M. del Tacca
Clinical cancer research : an official journal of…
2000
Corpus ID: 23450416
The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro…
Expand
2000
2000
Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers
H. Zhou
,
L. Choi
,
+9 authors
R. Capdeville
Journal of clinical pharmacology
2000
Corpus ID: 23998433
SAM486A (previously termed CGP 48664), a potent inhibitor of S‐adenosylmethionine decarboxylase, is under clinical development…
Expand
Highly Cited
1992
Highly Cited
1992
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
J. Wall
,
H. Burris
,
+13 authors
J. Kuhn
Anti-cancer drugs
1992
Corpus ID: 24090622
Topotecan (SK&F 104864) is a novel antitumor agent whose mechanism of action is inhibition of the DNA unwinding protein…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE